In recent years, Mannheimer Swartling's Health Care and Life Sciences group has developed a broad specialisation in issues which are of particular importance for pharmaceuticals/biotech, medical technology and health care companies.

• The group works with research-driven industry on a variety of issues. Topical areas have included the issue of co-operation and relationships between the industry and the health care sector, including everything from research and clinical trials to sponsoring and other benefits, the establishment of guidelines, marketing and handling of information, etc.
• Another area of great importance is the subsidy of pharmaceuticals and exchangeability issues, where we have extensive specialist competence regarding planning and preparation of applications to The Dental and Pharmaceutical Benefits Agency as well as appeals of The Dental and Pharmaceutical Benefits Agency’s decisions to courts of law.
•  A third important area is the protection against unfair competition from generic products. Current issues affect, among other things, exclusivity of documents and confidentiality, opportunities for innovative companies to intervene in different matters regarding simplified procedures, generic substitution, etc. The firm also sees a constantly growing need for advice regarding public procurement of products and services in the industry.

The list of industry-specific competence is long. Naturally, Mannheimer Swartling's specialists also works with, for example, licensing matters, permits, marking, distribution and parallel imports.